DEFR14A: LAVA Therapeutics Amends XOMA Acquisition Offer to $1.04 Cash

LAVA Therapeutics N.V. shareholders are invited to an Extraordinary General Meeting on November 7, 2025, to vote on XOMA Royalty Corporation's amended tender offer of $1.04 cash plus one Contingent Value Right per share.

Summary

• XOMA Royalty Corporation has made a tender offer to acquire all outstanding common shares of LAVA Therapeutics N.V. for $1.04 per share in cash, plus one Contingent Value Right (CVR) per share.
• The CVRs represent a contractual right to receive potential future cash payments from various sources, including 100% of Closing Net Cash exceeding $24.5 million, 75% of net proceeds from existing collaborations with Pfizer and Johnson & Johnson, and 75% of net proceeds from future dispositions of LAVA's CVR Products.
• XOMA estimates the CVRs to have an approximate value of $0.00 per CVR.
• The LAVA Board of Directors unanimously recommends that shareholders accept the offer and vote FOR all proposals at the Extraordinary General Meeting (EGM).
• The EGM is scheduled for November 7, 2025, to vote on the conditional appointment of four new directors designated by XOMA, the discharge of current board members, and resolutions for a post-offer reorganization (Downstream Merger and Cancellation).
• The offer's expiration date has been extended to November 12, 2025.
• The offer is subject to conditions, including a minimum tender of 80% (potentially 75%) of LAVA's outstanding shares and a Closing Net Cash of at least $24.5 million.
• LAVA management's dissolution analysis estimated a liquidation distribution of $0.95 per share, discounted to $0.89 per share as of December 31, 2025, which is less than the $1.04 cash offer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive, driven by the Board's unanimous recommendation and the cash offer being superior to liquidation. However, the significant uncertainty and estimated zero value of the CVRs, along with potential tax implications for non-tendering shareholders, temper the overall positive outlook.

Positives

• The offer provides immediate liquidity and certainty of value for LAVA shareholders at $1.04 per share in cash.
• The cash offer of $1.04 per share is higher than the estimated liquidation value of $0.95 per share (or $0.89 discounted to December 31, 2025).
• The transaction is not subject to any financing condition, increasing deal certainty.
• The CVRs offer shareholders an opportunity to participate in potential future proceeds from existing collaborations and future asset dispositions, as well as any excess closing net cash.
• The LAVA Board unanimously recommends the offer, believing it is in the best interests of the company and its stakeholders, given the lack of a viable standalone business plan.
• Buyer (XOMA) has extensive experience in executing asset dispositions and is financially incentivized to pursue dispositions of CVR Products.

Negatives

• The estimated value of the Contingent Value Rights (CVRs) by XOMA is approximately $0.00 per CVR, introducing significant uncertainty regarding additional payments.
• Shareholders will not participate in any future growth or earnings of LAVA as an independent entity.
• Non-tendering shareholders who receive consideration through the Post-Offer Reorganization may be subject to a 15% Dutch dividend withholding tax on amounts exceeding the average paid-up capital.
• The Purchase Agreement includes a termination fee of $750,000 payable by LAVA under certain circumstances, such as accepting a superior proposal.

Risks

• Significant uncertainty surrounds the actual value and realization of payments from the Contingent Value Rights (CVRs), as XOMA estimates their value at approximately $0.00.
• LAVA believes it may be classified as a Passive Foreign Investment Company (PFIC) for the current and prior taxable years, which could result in adverse U.S. federal income tax consequences for U.S. Holders.
• The offer may not be consummated if conditions, such as the minimum tender condition (80% or 75% of shares), are not met, leading to expended time and effort without a transaction.
• Potential litigation related to the offer or transactions could arise, incurring costs and distractions.
• The company would incur substantial transaction expenses, which would negatively impact cash reserves if the transaction is not completed.

Future Outlook

The transaction, if approved, will result in LAVA Therapeutics N.V. becoming a subsidiary of XOMA Royalty Corporation, delisting from Nasdaq, and ceasing to be a publicly traded company. Future value for LAVA shareholders will primarily depend on the $1.04 cash payment and any contingent payments realized from the CVRs, which XOMA currently estimates at $0.00. XOMA is obligated to use commercially reasonable efforts to maintain existing partnerships and pursue dispositions of CVR Products for a period of time.

Management Comments

• The Board has determined that, on the terms and subject to the conditions set forth in the Purchase Agreement, the Purchase Agreement and the transactions contemplated by the Purchase Agreement (including the Post-Offer Reorganization) are in the best interests of LAVA and the sustainable success of its business, having considered the interests of its shareholders, employees and other relevant stakeholders.
• The Board has resolved, on the terms and subject to the conditions set forth in the Purchase Agreement, to support the Offer and the other transactions contemplated by the Purchase Agreement and to recommend acceptance of the Offer by LAVA's shareholders and to recommend that the Company's shareholders vote FOR the EGM Proposals.

Industry Context

LAVA Therapeutics, a clinical-stage immuno-oncology company, is being acquired by XOMA Royalty Corporation, a biotech royalty aggregator. This transaction represents a strategic shift for LAVA, moving away from its standalone Gammabody platform development due to a lack of a viable standalone business plan, towards monetizing its existing assets and partnerships through XOMA's royalty aggregation model. The broader biotech industry has faced challenges in financing, which influenced LAVA's decision to pursue strategic alternatives including a sale or merger.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for a detailed assessment against global benchmarks. The comparison is primarily internal, against LAVA's estimated liquidation value.
• XOMA Royalty Corporation is described as a 'biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments,' indicating a business model focused on acquiring and managing such rights rather than direct drug development, which is a standard practice for such aggregators.

Management Changes

Corporate Governance

Legal Proceedings

• The filing acknowledges the possibility of lawsuits, actions, or proceedings related to the Purchase Agreement or the transactions, and outlines the company's and buyer's cooperation in defense and settlement.
• LAVA has agreed not to settle any such litigation without Buyer's prior written consent, with limited exceptions for insurance-covered settlements or those related solely to disclosure.

Related Party Transactions

• LAVA's directors and executive officers have interests in the offer that may differ from general shareholders, including accelerated vesting and payment of 'In-the-Money Options' at closing.
• Executive officers are eligible for severance payments and benefits under their existing employment agreements upon a qualifying termination during the change in control period.
• LAVA's directors and executive officers (holding approximately 0.5% of outstanding shares) have entered into Tender and Support Agreements, committing to tender their shares and vote in favor of the EGM proposals.

Stakeholder Impact

• Shareholders: Will receive $1.04 cash per share plus a CVR, which XOMA estimates at $0.00. Non-tendering shareholders may face Dutch dividend withholding tax. The offer is considered more favorable than liquidation.
• Employees: Executive officers may receive severance benefits. 401(k) plans may be terminated. The company's wind-down of clinical trials has already led to workforce reductions.
• Management: Current directors and executive officers will see accelerated vesting of in-the-money options and potential severance. Most current directors will step down, replaced by XOMA-designated individuals.
• Partners (Pfizer, Johnson & Johnson): Existing collaborations are CVR Products, meaning a portion of future proceeds from these partnerships will be distributed to CVR holders. XOMA is obligated to maintain and enforce these agreements.
• Creditors: Following the Downstream Merger, creditors of LAVA will be able to recover claims from New Topco.

Next Steps

• Shareholders to vote on EGM proposals by November 6, 2025 (proxy) or November 7, 2025 (in person).
• Extraordinary General Meeting (EGM) to be held on November 7, 2025.
• Offer to expire on November 12, 2025, unless further extended.
• If conditions are met, Buyer will accept and pay for tendered shares promptly after expiration.
• A subsequent offering period of five business days will follow the Offer's expiration.
• If Post-Offer Reorganization Resolutions are adopted and threshold achieved, a corporate reorganization (Downstream Merger and Cancellation) will be effectuated.
• LAVA shares will be delisted from Nasdaq and deregistered under the Exchange Act after the Closing.

Key Dates

Recommendation

The LAVA Board of Directors unanimously recommends that shareholders accept the offer, stating it is in the 'best interests' of the company and its stakeholders and 'more favorable' than the alternative of liquidation. The cash component of $1.04 per share exceeds the estimated liquidation value of $0.89 per share (discounted). While the Contingent Value Right (CVR) is estimated at $0.00 by XOMA, the guaranteed cash portion provides a clear, superior return compared to the company's standalone prospects. Therefore, for existing shareholders, tendering shares into the offer is the recommended action. For potential investors, buying shares to tender into the offer would secure this premium over liquidation value.

Keywords

Tender Offer, Acquisition, LAVA Therapeutics, XOMA Royalty Corporation, Contingent Value Rights, CVR, Biotechnology, Immuno-oncology, SEC Filing, Corporate Reorganization, Shareholder Vote, Merger, Dutch Law, PFIC